Utility of whole-body diffusion-weighted magnetic resonance imaging in the management of treatment-related neuroendocrine prostate cancer.

Autor: Kurashina R; Department of Urology Dokkyo Medical University Tochigi Japan., Kijima T; Department of Urology Dokkyo Medical University Tochigi Japan., Okazaki A; Department of Urology Dokkyo Medical University Tochigi Japan., Fuchizawa H; Department of Urology Dokkyo Medical University Tochigi Japan., Suzuki I; Department of Urology Dokkyo Medical University Tochigi Japan., Sakamoto K; Department of Urology Dokkyo Medical University Tochigi Japan., Betsunoh H; Department of Urology Dokkyo Medical University Tochigi Japan., Fukabori Y; Department of Urology Dokkyo Medical University Tochigi Japan., Yashi M; Department of Urology Dokkyo Medical University Tochigi Japan., Kamai T; Department of Urology Dokkyo Medical University Tochigi Japan.
Jazyk: angličtina
Zdroj: IJU case reports [IJU Case Rep] 2020 Nov 29; Vol. 4 (2), pp. 69-73. Date of Electronic Publication: 2020 Nov 29 (Print Publication: 2021).
DOI: 10.1002/iju5.12242
Abstrakt: Introduction: Treatment-related neuroendocrine prostate cancer, a rare and aggressive malignancy that emerges during androgen deprivation therapy characterized by low serum prostate-specific antigen concentrations, is challenging to monitor because it is associated with predominantly visceral and lytic bone metastases.
Case Presentation: We describe the case of a 69-year-old man with treatment-related neuroendocrine prostate cancer in whom the treatment response could be monitored using whole-body diffusion-weighted magnetic resonance imaging in addition to serum concentrations of neuroendocrine markers. The patient responded well to platinum-based chemotherapy and achieved a complete response, as evidenced by these diagnostic modalities.
Conclusion: Our case suggests that whole-body diffusion-weighted magnetic resonance imaging is useful in disease management for treatment-related neuroendocrine prostate cancer as well as the potential evaluation of mixed responses and treatment resistance.
Competing Interests: The authors declare no conflict of interest.
(© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.)
Databáze: MEDLINE
Externí odkaz: